This multicenter, prospective, observational, non-interventional study investigates patients with intracranial hemorrhage under effective anticoagulation with dabigatran or vitamin-K antagonist (VKA). Routine data will be collected during hospitalization. Patients aged 18 years or older under effective therapy with dabigatran and symptomatic intracranial bleeding confirmed by cerebral imaging and treated with idarucizumab will be compared to patients under effective treatment with VKA at the time of onset of the intracranial bleeding. Ninety-five dabigatran patients who provided written informed consent for data transmission will be included. As control group retrospective and anonymized data of 285 VKA patients patients under VKA treatment and admitted to RIC-ICH study centers will be used. For each patient receiving idarucizumab, three patients with intracranial hemorrhage under effective treatment with VKA, will be included (retrospective) in the study. In addition, data of VKA patients will be transferred from the RASUNOA-PRIME and the "Erlanger Hirnblutungs-Register".

Start Date19 Sep 2019

Sponsor / Collaborator

University Hospital Of Essen

NCT02798107

/ WithdrawnNot Applicable

Safety of Potential Paediatric Patients Treated With Idarucizumab: a Non-internventional Chart Review Study

Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity. Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises its anticoagulant effect. A clinical development program is ongoing to support marketing authorisation submissions for idarucizumab indicated in patients treated with dabigatran who require emergency surgery/urgent procedures or who have a life-threatening or uncontrolledbleeding when rapid reversal of the anticoagulant effects of dabigatran is required.

Start Date20 May 2019

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT03359889

/ CompletedNot Applicable

Post Marketing Surveillance Program of Praxbind Use in India.

This program will be initiated after the commercial availability of PraxbindTM in India. It will include patients administered with PraxbindTM into the surveillance program after commercial availability in 2 years at selected centres approved by the regulatory authority.

Start Date26 Dec 2018

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Idarucizumab

100 Translational Medicine associated with Idarucizumab

100 Patents (Medical) associated with Idarucizumab

569

Literatures (Medical) associated with Idarucizumab

01 Mar 2025·BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet‐α, protamine)

Review

Author: Liakoni, Evangelia ; Bekka, Elias

Bleeding events are common in patients prescribed anticoagulants and can have devastating consequences. Several specific and nonspecific agents have been developed to reverse the effects of anticoagulant drugs or toxins. Vitamin K, as the oldest of these antidotes, specifically counteracts the effects of pharmaceuticals and rodenticides designed to deplete stores of vitamin K‐dependent factors. In cases of life‐threatening bleeding, the addition of prothrombin complex concentrates (PCCs) allows for the immediate replacement of coagulation factors. While the use of PCCs has been extended to the non‐specific reversal of the effects of newer direct oral anticoagulants, the specific agents idarucizumab, targeting dabigatran and andexanet‐α, binding factor Xa inhibitors, have recently been developed and are being preferentially recommended by most guidelines. However, despite having rapid effects on correcting coagulopathy, there is to date a lack of robust evidence establishing the clear superiority of direct oral anticoagulant‐specific reversal agents over PCCs in terms of haemostatic efficacy, safety or mortality. For andexanet‐α, a potential signal of increased thromboembolic risks, comparatively high costs and low availability might also limit its use, even though emerging evidence appears to bolster its role in intracranial haemorrhage. Protamine is the specific agent for the reversal of unfractionated heparin anticoagulation used mainly in cardiovascular surgery. It is much less effective for low molecular weight heparin fragments and is usually reserved for cases with life‐threatening bleeding.

05 Feb 2025·Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko

Correction of the effect of direct oral and parenteral anticoagulants in hemorrhagic stroke

Review

Author: Baranich, A.I. ; Sychev, A.A. ; Savin, I.A. ; Kudrina, V.G. ; Kozlov, A.V.

Background. Hemorrhagic stroke is associated with high risk of adverse outcome and follows intake of anticoagulants and antiplatelet agents in 25% of cases. The latest clinical guidelines of the Neurocritical Care Society for correction (reversal) of the effect of anticoagulants and antiplatelet agents in hemorrhagic stroke were published in 2016. Material and methods. In accordance with PRISMA recommendations, we reviewed the PubMed, eLibrary and UpToDate databases to a depth of 5 years and selected 48 articles. Results and discussion. Direct oral anticoagulants are currently common. To reverse their effect, one can use specific antidotes (idarucizumab is recommended for dabigatran, andexanet alfa (not yet registered In Russia) for factor Xa inhibitors (rivaroxaban, apixaban)) and combination of prothrombin complex concentrate and tranexamic acid. Protamine sulfate is antidote for unfractionated and low molecular weight heparins. Protamine sulfate completely inactivates unfractionated heparin, but it is less effective against low molecular weight heparin. It is characterized by high probability of anaphylactic reactions, especially after repeated administrations. The effectiveness of andexanet alpha and activated factor VII for reversing the effect of low molecular weight heparin is being studied. Fondaparinux sodium is used for heparin-induced thrombocytopenia. Protamine sulfate is ineffective for reversing the effect of fondaparinux. One can use prothrombin complex concentrate and andexanet alpha, but their effectiveness is unclear. Ciraparantag is being studied in clinical trials. Apparently, ciraparantag is highly effective as an antidote for various anticoagulants. Conclusion. Early hemostatic therapy and reversal of anticoagulant effects in patients with hemorrhagic stroke significantly reduce the risk of adverse outcomes. This problem is being studied. Regular literature review with creation of updated clinical guidelines is needed.

01 Feb 2025·PHARMACOTHERAPY

Intravenous thrombolysis for patients with acute ischemic stroke while receiving a direct oral anticoagulant: A systematic review and meta‐analysis

Review

Author: Starr, Jessica A. ; Pinner, Nathan A. ; Roberts, Megan Z. ; Durham, Spencer H.

Abstract:

Recent guidelines for acute ischemic stroke (AIS) indicate administration of intravenous thrombolysis (IVT) in patients receiving direct oral anticoagulants (DOAC) is not firmly established and may be harmful unless certain potential parameters are met. This systematic review and meta‐analysis explores safety outcomes and other clinical parameters from the growing number of publications describing patients taking a DOAC who experience an AIS that is treated acutely with IVT alone. Embase, International Pharmaceutical Abstracts, and PubMed were searched up to January 9, 2024 for studies including adult patients taking a DOAC who experienced an AIS treated with IVT and did not undergo endovascular therapy (EVT), regardless of the use of an anticoagulation reversal agent. Primary safety outcomes evaluated included symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage, and in‐hospital mortality. A total of 873 patients from 78 studies, primarily case reports or case series of patients receiving dabigatran with or without idarucizumab reversal (n = 340), were included in the review. The rate of sICH during the index hospitalization was 3.3%. Seven high‐quality studies with low risk of bias included outcomes for patients on DOAC and comparator groups of either patients not taking an oral anticoagulant (no OAC) or patients taking a vitamin K antagonist (VKA) with INR primarily <1.7 at the time of AIS. No significant difference was observed in the incidence of sICH among patients receiving DOAC vs. no OAC (odds ratio [OR] 0.8, 95% confidence interval [CI]: 0.48–1.33) or among patients receiving DOAC vs. VKA (OR 1.02, 95% CI 0.59–1.75). Similar findings of no difference were observed for other safety outcomes. Findings from this study suggest that utilization of IVT as sole recanalization therapy for AIS may be safe in patients taking a DOAC; however, further studies are needed to elucidate specific parameters that differentiate timepoints and variables to ensure safe, optimal treatment.

News (Medical) associated with Idarucizumab

11 Sep 2024

·www.biospace.com

Feinstein Institutes Research Suggests New Management Protocols for Patients Taking Oral Anticoagulants

MANHASSET, N.Y.--(BUSINESS WIRE)--Direct oral anticoagulants (DOACs) are commonly used medications that help prevent blood clots, which can be dangerous for those suffering from heart conditions or at risk of venous thromboembolism. However, these medications can also increase the likelihood of bleeding, especially during surgeries. Researchers at the Feinstein Institutes for Medical Research recently published in the Journal of the American Medical Association (JAMA) protocols to effectively manage the administration of DOACs and minimize bleeding and clotting risks – suggesting new conventions for patients pre- and post-surgery. Approximately 4 million patients in the United States are currently being treated with DOAC therapy. The review paper, titled “Perioperative Management of Patients Taking Direct Oral Anticoagulants,” analyzed how physicians should handle a patient’s blood thinner medicine depending on whether a procedure is surgical and to what degree of risk a procedure presents. The paper reviewed 99 articles on blood thinners and surgery to inform its evaluation. The authors concluded that doctors must assess the bleeding risk (low, medium, or high) of a planned surgery. Additionally, the research recommends that standardized management protocols – which do not require testing DOAC levels, heparin bridging, or short-acting anticoagulants – can be safely and effectively used for patients undergoing elective or non-urgent procedures. However, for patients on DOACs who require emergency, urgent, or semi-urgent surgery, using anticoagulant reversal agents may be appropriate if DOAC levels are elevated or unavailable. “When patients taking DOAC blood thinners undergo an optional or nonsurgical procedure, doctors can follow a simple standardized management plan where they won’t need to administer a blood test to check DOAC levels or use heparin, an alternate blood thinner,” said Alex C. Spyropoulos, MD , professor at Feinstein Institutes’ Institute of Health System Science . “Through this careful review, we determine that urgent or emergent procedures are another story and may need additional therapy and monitoring to prevent complications.” Patients who require urgent or emergency surgeries may need additional medications that quickly reverse the effects of DOACs if bleeding occurs during the procedure. One type of reversal agent (examples include andexanet-α for edoxaban, rivaroxaban , or apixaban and idarucizumab for dabigatran) can help with specific DOACs, while a more general reversal agent called prothrombin complex concentrate (PCC) can reverse the effects of any DOAC medication, albeit less effectively. “A leader in the field, Dr. Spyropoulos advances patient care through his research,” said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes and the Karches Family Distinguished Chair in Medical Research at Northwell Health. “His new insights into preventing life-threatening blood clots during elective procedures have the potential to benefit countless patients at Northwell Health and globally.” In addition to this JAMA article, and investigating a blood clot prevention treatment called thromboprophylaxis – particularly in relation to the treatment of hospitalized COVID-19 patients – Dr. Spyropoulos and his co-authors recently published an article in the Journal of Thrombosis and Haemostasis that determined hospitals’ incorporation of a user-friendly clinical decision support tool can also significantly improve the appropriate use of blood clot prevention strategies. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, translational research, and molecular medicine. We make breakthroughs in health condition, including endometriosis, lupus, postpartum depression, schizophrenia, sepsis. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn . Contacts Matthew Libassi 631-793-5325 mlibassi@northwell.edu

13 Nov 2023

·synapse.patsnap.com

Analysis on the Clinical Research Progress of Fab Fragment

The Fab fragment, also known as the antigen-binding fragment, is the region of an antibody that can bind with antigens. The Fab fragment consists of a complete light chain and the VH and CH1 structural domains (Fd segment) of the heavy chain, with a molecular weight of approximately 50,000. Both the light and heavy chains contain a constant region and a variable region, with disulfide bonds linking the two chains. As Fab possesses both an antigen-binding site and a part of the constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration ability as a single-chain antibody (scFv), but also a more stable structure. Therefore, it plays a significant role in clinical diagnosis and treatment. Compared with the complete IgG, the Fab fragment lacks the Fc region and, although it can selectively bind to the antigen, it does not precipitate. Due to its low autoimmunogenicity, it can't be recognized by living immune cells, thereby significantly reducing the likelihood of hypersensitivity reactions and enhancing the safety of a product. Fab-class antibody fragments have the characteristics of low molecular weight, strong tissue distribution specificity, low immunogenicity, and manipulability through gene engineering, making Fab an essential member in the field of pharmaceutical research. Fab-class drugs are widely applied in prevention, diagnosis, and treatment fields. Fab Fragment Competitive LandscapeAccording to Patsnap Synapse, as of 8 Oct 2023, there are a total of 69 Fab fragment drugs worldwide, from 115 organizations, covering 35 targets, 110 indications, and conducting 918 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, targets, organizations, clinical trials, and clinical results related to this drug type. Approved Fab Fragment Medicinal: IdarucizumabIdarucizumab is a drug that falls under the category of Fab fragment, monoclonal antibody in the field of biomedicine. It is designed to target dabigatran, a medication used to prevent blood clots. The therapeutic areas in which Idarucizumab is used include hemic and lymphatic diseases, as well as other diseases. The drug is primarily indicated for the treatment of blood coagulation disorders and hemorrhage. Idarucizumab was developed by Boehringer Ingelheim GmbH, a pharmaceutical company. It has received approval for use in the highest phase globally, indicating that it has successfully completed clinical trials and met the necessary regulatory requirements. The first approval of Idarucizumab took place in the United States in October 2015. This signifies that it was the first country to grant regulatory approval for the drug. Additionally, Idarucizumab is classified as an orphan drug, which means it is intended to treat rare diseases or conditions that affect a small number of individuals. In summary, Idarucizumab is a Fab fragment, monoclonal antibody drug developed by Boehringer Ingelheim GmbH. It targets dabigatran and is used in the treatment of blood coagulation disorders and hemorrhage. The drug has received approval in global markets, with its first approval occurring in the United States in October 2015. Idarucizumab is classified as an orphan drug, indicating its intended use for rare diseases or conditions. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Approved Fab Fragment Medicinal: Certolizumab PegolCertolizumab Pegol is a drug that falls under the category of Fab fragment, Monoclonal antibody. It specifically targets TNF-α, which is a protein involved in the immune system response. The drug has been approved for use in various therapeutic areas, including Immune System Diseases, Congenital Disorders, Hemic and Lymphatic Diseases, Nervous System Diseases, Skin and Musculoskeletal Diseases, Infectious Diseases, and Digestive System Disorders. Certolizumab Pegol has been indicated for the treatment of several conditions, such as Erythrodermic psoriasis, Psoriasis vulgaris, Pustular psoriasis, Non-radiographic axial spondyloarthritis, Ankylosing Spondylitis, Plaque psoriasis, Arthritis (Psoriatic and Rheumatoid), Axial Spondyloarthritis, Crohn Disease, Psoriasis, Multiple Sclerosis, and Granulomatous Disease, Chronic. The drug was developed by UCB SA, an originator organization in the pharmaceutical industry. It has received approval in multiple countries, with its first approval granted in the United States in April 2008. Certolizumab Pegol has undergone priority review, indicating its potential significance in addressing unmet medical needs or providing a substantial improvement over existing treatments. As a Fab fragment, Monoclonal antibody targeting TNF-α, Certolizumab Pegol offers a promising therapeutic option for a wide range of diseases affecting various body systems. Its approval in multiple countries, including the United States, highlights its effectiveness and safety profile. The drug's diverse therapeutic areas indicate its potential to address multiple medical conditions, ranging from immune system disorders to digestive system disorders. Certolizumab Pegol's approval in China further expands its reach and potential patient population. The drug's highest phase being approved globally signifies its advanced stage of development and successful clinical trials. With its first approval dating back to 2008, Certolizumab Pegol has established a significant presence in the pharmaceutical market, providing healthcare professionals and patients with a valuable treatment option. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Overall, Certolizumab Pegol's approval, therapeutic areas, and target specificity make it a noteworthy drug in the field of biomedicine. Its originator organization, UCB SA, has contributed to the advancement of pharmaceutical research and development, bringing innovative therapies to patients worldwide.

17 Aug 2022

·www.biospace.com

High Prevalence Of Respiratory Disorders Is Expected To Boost Growth Prospects For High-Flow Nasal Cannula Market During The Forecast Period

The Acute Respiratory Failures Segment Is Expected To Grow Impressively At A CAGR Of 11.4% Fact.MR – A Market Research and Competitive Intelligence Provider: The global high-flow nasal cannula market is expected to witness a CAGR of 11.8% during the forecast period (2020 – 2025). Technological advancements by key market players are also expected to offer opportunities and new avenues for the market. High prevalence of acute respiratory failures is expected to offer lucrative opportunities for high-value oxygen therapy using high-flow nasal cannula. Other benefits of high-flow nasal cannula are that they deliver a consistent flow of oxygen via the nasal cannula and alleviate upper airway obstruction. Moreover, rise in prevalence of sleep apnea is also anticipated to boost the market growth. High prevalence of non-invasive ventilation and continuous positive airway pressure devices has risen rapidly in home care settings for patients suffering from respiratory diseases. This has also pushed key manufacturers to increase production of devices, thus boosting the market share. For more insights into the Market, Request Brochure of this Report Moreover, increasing population, growing smoking prevalence and degraded air quality have boosted the number of respiratory disease cases. Key players in the market are expanding its production of respiratory support, ventilators and humidification products to hospitals. For instance, ResMed has boosted the production of its devices such as AirCurve 10 bi-level devices to offer some comfort to Covid-19 patients. Key Takeaways: The Acute Respiratory Failures segment is expected to account for around 3/10th of the high-flow nasal cannula market, growing rapidly at a CAGR of 11.4% Rising prevalence of sleep apnea is also expected to boost the market of high-flow nasal cannula. Moreover, market is projected to witness a CAGR of 13.5% during the forecast period. Asia pacific is expected to show impressive growth prospects fro the high-flow nasal cannula market. Moreover, Asia pacific is also expected capture a market share of13.2% Growth Drivers: Covid-19 pandemic has boosted the market aspects for high-flow nasal cannula market. Moreover, owing to its widespread application in the treatment of respiratory diseases, high-flow nasal cannula is gaining traction. Also, as the Covid-19 affects the lungs, high-flow nasal cannula is suitable approaches to aid patients breathe normally. Rising prevalence of respiratory diseases is anticipated to boost the high-flow nasal cannula market during the forecast period. Moreover, growing smoking prevalence have also increased the number of respiratory diseases cases across the globe. Growing acceptance of high-flow nasal cannula treatment among various patients is expected to boost the growth of the market Key players in the market are making significant investments in the product portfolio. Companies are significantly investing in technological advancements to acquire market share. Surge in cases of sleep apnea is also expected to boost the growth of high-flow nasal cannula. For Comprehensive Insights Ask An Analyst Here Competitive Landscape: The global high-flow nasal cannula market is fragmented. Out of the major key players, four of these account for the maximum share, three-tenth of the total market. These four players are BD/CareFusion, Fisher & Paykel Healthcare Limited, Telefax incorporated, and ResMed Inc. Moreover, these players are significantly innovating product portfolios by investing into technological advancements to acquire market presence. For instance, Fisher & Paykel is boosting its production of respiratory support devices, ventilators and humidification products to hospitals. Likewise, ResMed has accelerated its production of its AirCurve 10 bi-level devices to provide some comfort to COVID-19 patients. ResMed Inc. is key player in the market. It offers various products for the treatment of sleep apnea and non-invasive ventilation. Also, flagship products include AirView, ClimateLine Max and myAir for the management of sleep apnea and respiratory disorders. Key Companies Profiled by Fact.MR More Valuable Insights on High-flow nasal cannula market By Component: Air/Oxygen Blend Air Humidifier Single Heated Tube Nasal Cannula Other Consumables By Application: Acute Respiratory Failure Chronic Obstructive Pulmonary Disease (COPD) Carbon Monoxide Toxicity Bronchiectasis Sleep Apnea Other Applications By End-user: Hospitals Long-term Care Centers Ambulatory Care Centers Tomosynthesis Other End-users Key Regions: North America Europe Asia Pacific Latin America Middle East & Africa Get Customization on this Report for Specific Research Solutions Explore Fact.MR’s Coverage on the Healthcare Domain Animal Genetics Market - The development of progressive genetic modification practices is leading to the high production of animals with modified breeds, thereby attracting investments from end users. Antacids Market - Manufacturers in the antacids market are approaching drug formulation techniques through consumer-centric means, in the form of chewable and flavored tablets, to score well in convenience regards. On the back of these factors, the exhaustive study by Fact.MR pegs the global antacids markets to soar to ~US$ 19 Bn by 2025. Antimicrobial Susceptibility Test Market - Rising government initiatives regarding the development of quality hospital infrastructure, on a global level, and surging susceptibility to infectious diseases, are projected to complement the demand for antimicrobial susceptibility tests in diagnostic laboratories and hospitals during the forecast period (2020-2025). Anticoagulant Reversal Drugs Market - Sales of Idarucizumab increased 19% Y-o-Y in 2019 over 2018. However, according to the estimation of a seasoned analyst at Fact.MR, year-over-year sales of the same drug will witness a sharp decrease of 11% in 2026 over 2025. Anticancer Drugs Market - Development of therapeutics with better patient outcomes and lesser side-effects than conventional ones is projected to increase patients’ trust in these drugs, thereby strengthening the growth prospects of the anticancer drugs market. Apheresis Market - Lack of regular blood donors is being countered by private blood collection centres that attract donors through paid plans. In recent times, hospitals are increasing the adoption of apheresis equipment to collect and store required blood components, so as to reduce dependency on private suppliers and blood collection centres. Aptamers Market - Advent of the chemical modification process to increase the nuclease resistance of aptamers, and, in turn, enhance their therapeutic properties creates opportunities galore for players in the aptamer market. Dental 3D Printing Market - Development of customized dental models such as bridges, crowns, implants, and dentures is offering better patient outcomes, and, in turn, boosting the reliance of dentists on printed prosthetics. Behavioural Health Treatment Market - The advent of the on-demand service model underpinning the concepts of tele psychiatry offers the choice to patients to avail home-based treatment services. Besides enhancing the comfort feature, home-based treatment services also offer significant cost benefits and reduced wait times. Assisted Reproductive Technology Market - Studying the relevance of all the crucial dynamics, Fact.MR, in its latest study, forecasts that revenue of the assisted reproductive technology market would witness an annual increase of around 6.3% in 2020. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making. We provide both qualitative and quantitative research, spanning market forecast, market segmentation, competitor analysis, and consumer sentiment analysis. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter

100 Deals associated with Idarucizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10741	Idarucizumab	V03AB37	DB09264

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemorrhage	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	16 Oct 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Venous Thromboembolism	Phase 3	Russia	Boehringer Ingelheim GmbH	07 Sep 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISTH2023	Not Applicable	-	3,465	Idarucizumab	yfppqripzl(jtlkaehkrm) = vufuyvqgwo lyfjpryjpd (nggctmxjej, 11.5 - 19.6) View more	-	24 Jun 2023
ISTH2022	Not Applicable	-	101	Idarucizumab	kwzunaamfj(hnfqrcukli) = ygowuctaqn cmckpgdnfh (gwvsbiuerg )	-	09 Jul 2022
ISTH2022	Not Applicable	-	46	Idarucizumab	jiohjdxhgm(mdztkxsuas) = achtxhgkwd qxedtxiilb (geqfxubneo )	-	09 Jul 2022
ISTH2022	Not Applicable	-	6	Idarucizumab	afjowwnjuh(jfjlpakqjb) = jzelvbfpsu ebdwoukvrj (wvomstszku ) View more	Positive	09 Jul 2022
NCT03343704 (CTgov)	Phase 3	Hemorrhage	19	Idarucizumab (Group A - Patients With Uncontrolled or Life-threatening Bleeding)	tvnbsjnrro(jrkutfmitn) = iwupaadzhm pocokldpny (wtgtzdzmor, pnabujmgzb - bcjpxoluul) View more	-	20 Aug 2021
NCT03343704 (CTgov)	Phase 3	Hemorrhage	19	Idarucizumab (Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure)	tvnbsjnrro(jrkutfmitn) = wnjolqzyqj pocokldpny (wtgtzdzmor, ksfsyrnxlu - zcznzzpqwd) View more	-	20 Aug 2021
ISC2021	Not Applicable	Hemorrhage	-	Idarucizumab	sfbhrgjaru(emlsaqqjqx) = zcajjtjigw xqfwvufqfc (qrbfwjbxpk )	-	01 Mar 2021
ISC2021	Not Applicable	Hemorrhage	-	Andexanet Alfa	sfbhrgjaru(emlsaqqjqx) = ysmuywrelt xqfwvufqfc (qrbfwjbxpk )	-	01 Mar 2021
ESC2020	Not Applicable	-	-	Idarucizumab	omtnidwjxn(mjnleycrgo) = cjjcbtwgrl kfybouvbdh (uzqyicidtt, 3.4 - 5.0) View more	-	28 Aug 2020
ISTH2020	Not Applicable	-	26	Praxbind 5g	djxckjfpdv(wmuswbrliw) = yputtfmqyq qzbqjckjfn (pglysvltkb )	-	12 Jul 2020
ISTH2020	Not Applicable	-	26	Praxbind 2.5g	djxckjfpdv(wmuswbrliw) = hcqfqtylvg qzbqjckjfn (pglysvltkb )	-	12 Jul 2020
ISTH2020	Not Applicable	-	7	Idarucizumab	hhrtvhwukl(tanefgsndp) = faxzevscap mxilunakip (bzdnnpwgby )	-	12 Jul 2020
NCT02815670 (CTgov)	Phase 3	Hemorrhage \| Venous Thromboembolism	1	Idarucizumab	acinklrmwz = mgpieccjxg uuxyqgnvus (lslousiisv, cevkzlwqbg - uldhmdryie) View more	-	14 Apr 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis